Healthcare provider profile · identity verified

Roberto Sandoval Rodriguez, M.D.

Internal Medicine · CAYEY, PR · NPI 1477542736

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	1098	400
Losartan Potassium	Losartan Potassium	598	216
Amlodipine Besylate	Amlodipine Besylate	555	206
Synthroid	Levothyroxine Sodium	490	136
Metformin Hcl	Metformin Hcl	485	174
Gabapentin	Gabapentin	459	172
Lisinopril	Lisinopril	435	147
Levothyroxine Sodium	Levothyroxine Sodium	362	136
Simvastatin	Simvastatin	307	110
Metoprolol Succinate	Metoprolol Succinate	305	117
Hydrochlorothiazide	Hydrochlorothiazide	256	83
Rosuvastatin Calcium	Rosuvastatin Calcium	254	103
Famotidine	Famotidine	213	84
Tamsulosin Hcl	Tamsulosin Hcl	175	74
Irbesartan	Irbesartan	153	52
Clopidogrel	Clopidogrel Bisulfate	141	55
Montelukast Sodium	Montelukast Sodium	135	63
Lantus	Insulin Glargine,hum.Rec.Anlog	134	32
Pantoprazole Sodium	Pantoprazole Sodium	131	53
Glimepiride	Glimepiride	121	44
Janumet	Sitagliptin Phos/Metformin Hcl	108	19
Farxiga	Dapagliflozin Propanediol	107	21
Omeprazole	Omeprazole	106	46
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	105	38
Sertraline Hcl	Sertraline Hcl	99	43
Januvia	Sitagliptin Phosphate	95	20
Eliquis	Apixaban	92	24
Furosemide	Furosemide	91	37
Humulin N	Insulin Nph Human Isophane	90	18
Doxazosin Mesylate	Doxazosin Mesylate	89	32
Alendronate Sodium	Alendronate Sodium	75	35
Omega-3 Acid Ethyl Esters	Omega-3 Acid Ethyl Esters	75	41
Atenolol	Atenolol	74	25
Donepezil Hcl	Donepezil Hcl	72	39
Irbesartan-Hydrochlorothiazide	Irbesartan/Hydrochlorothiazide	71	28
Enalapril Maleate	Enalapril Maleate	64	23
Pioglitazone Hcl	Pioglitazone Hcl	64	32
Xarelto	Rivaroxaban	63	14
Fenofibrate	Fenofibrate	57	37
Glipizide	Glipizide	57	26
Oxybutynin Chloride	Oxybutynin Chloride	57	25
Finasteride	Finasteride	56	22
Nifedipine Er	Nifedipine	55	24
Candesartan Cilexetil	Candesartan Cilexetil	49	20
Buspirone Hcl	Buspirone Hcl	48	21
Ezetimibe	Ezetimibe	45	21
Isosorbide Mononitrate Er	Isosorbide Mononitrate	45	20
Duloxetine Hcl	Duloxetine Hcl	44	18
Glipizide Er	Glipizide	44	14
Entresto	Sacubitril/Valsartan	43	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	40	22
Carvedilol	Carvedilol	39	17
Metoprolol Tartrate	Metoprolol Tartrate	39	15
Pravastatin Sodium	Pravastatin Sodium	38	14
Trazodone Hcl	Trazodone Hcl	38	23
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	36	15
Fluticasone Propionate	Fluticasone Propionate	34	21
Humulin 70-30	Insulin Nph Hum/Reg Insulin Hm	32	suppressed
Jardiance	Empagliflozin	32	12
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	31	12
Humalog	Insulin Lispro	30	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	30	11
Jentadueto	Linagliptin/Metformin Hcl	26	suppressed
Memantine Hcl	Memantine Hcl	26	14
Allopurinol	Allopurinol	25	12
Spironolactone	Spironolactone	25	suppressed
Warfarin Sodium	Warfarin Sodium	25	suppressed
Clotrimazole	Clotrimazole	24	20
Fenofibric Acid	Fenofibric Acid (Choline)	23	12
Clonazepam	Clonazepam	22	suppressed
Janumet Xr	Sitagliptin Phos/Metformin Hcl	22	suppressed
Prednisone	Prednisone	22	17
Trueplus Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	22	suppressed
Latanoprost	Latanoprost	20	suppressed
Sucralfate	Sucralfate	20	suppressed
Trijardy Xr	Empaglifloz/Linaglip/Metformin	20	suppressed
Trueplus Insulin Syringe	Syring-Needl,disp,insul,0.3 Ml	20	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	19	11
Humulin R	Insulin Regular, Human	19	suppressed
Hydralazine Hcl	Hydralazine Hcl	19	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	18	suppressed
Lansoprazole	Lansoprazole	18	suppressed
Nabumetone	Nabumetone	18	11
Oxybutynin Chloride Er	Oxybutynin Chloride	18	suppressed
Pentoxifylline	Pentoxifylline	18	suppressed
Tradjenta	Linagliptin	18	suppressed
Valsartan	Valsartan	18	suppressed
Breo Ellipta	Fluticasone/Vilanterol	16	suppressed
Hydrocortisone	Hydrocortisone	16	11
Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	16	suppressed
Temazepam	Temazepam	16	suppressed
Trulicity	Dulaglutide	16	suppressed
Metformin Hcl Er	Metformin Hcl	15	suppressed
Terazosin Hcl	Terazosin Hcl	15	suppressed
Bisoprolol Fumarate	Bisoprolol Fumarate	14	suppressed
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	14	suppressed
Dexamethasone	Dexamethasone	14	13
Nitrofurantoin	Nitrofurantoin Macrocrystal	14	12
Bisoprolol-Hydrochlorothiazide	Bisoprolol/Hydrochlorothiazide	13	suppressed
Diltiazem 24hr Er	Diltiazem Hcl	13	suppressed
Meloxicam	Meloxicam	13	suppressed
Synjardy	Empagliflozin/Metformin Hcl	13	suppressed
Synjardy Xr	Empagliflozin/Metformin Hcl	13	suppressed
Verapamil Er	Verapamil Hcl	13	suppressed
Verapamil Hcl	Verapamil Hcl	13	suppressed
Ramipril	Ramipril	12	suppressed
Alfuzosin Hcl Er	Alfuzosin Hcl	11	suppressed
Diclofenac Potassium	Diclofenac Potassium	11	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	11	suppressed
Isosorbide Dinitrate	Isosorbide Dinitrate	11	suppressed
Levofloxacin	Levofloxacin	11	11
Methotrexate	Methotrexate Sodium	11	suppressed
Propranolol Hcl	Propranolol Hcl	11	suppressed
Rivastigmine	Rivastigmine	11	suppressed
Tizanidine Hcl	Tizanidine Hcl	11	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error